Pfizer withdraws sickle cell disease treatment on risk of …
WEB4 days ago · Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. It reported $328 million in revenues from the therapy for the full year 2023.
FDA is alerting patients and health care professionals about the ...
WEB3 days ago · Pfizer Inc., the manufacturer of Oxbryta, announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded ...
MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal
WEB2 days ago · SCDAA Medical and Research Advisory Committee (MARAC) Statement: Voxelotor (Oxbryta®) 9/27/24. What is the news? Pfizer announced the withdrawal of voxelotor (Oxbryta®) from national and global markets on September 25, 2024. Clinical research was also stopped. “Pfizer’s decision is based on the totality of …
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB4 days ago · NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB5 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer decision to withdrawal sickle cell drug leaves patients ... - STAT
WEB4 days ago · Sept. 26, 2024. Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and ...
FDA alerts patients about Pfizer's Oxbryta withdrawal
WEB3 days ago · Sept 26 (Reuters) - The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's (PFE.N) sickle cell disease treatment Oxbryta ...
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB3 days ago · Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
Pfizer to pull sickle cell drug from market, shut down trials
WEB4 days ago · Dive Brief: Pfizer is pulling the sickle cell disease drug Oxbryta off the market and ending clinical trials of the medicine around the world due to safety concerns. Clinical data “now indicates that the overall benefit of Oxbryta no longer outweighs the risk,” Pfizer said Wednesday. The company said data show an imbalance of deaths and ...
Pfizer withdraws sickle cell treatment due to safety concerns
WEB3 days ago · Pfizer has voluntarily withdrawn its sickle cell disease treatment Oxbryta (voxelotor) from the market due to safety concerns. The Food and Drug Administration (FDA) recommends clinicians stop prescribing the treatment and patients talk to their doctor about starting a different treatment. “I am disappointed as many other providers, patients and families (are),” said Banu Aygun, M.D., FAAP ...
- Some results have been removed
Skip to content